Capacités
Un site. Quatre lignes de capacités. Un catalogue conçu pour les accueillir toutes deux.
Naprod fabrique des injectables oncologiques, anesthésiques et de soins critiques, ainsi que les comprimés, gélules et principes actifs qui les accompagnent, depuis un site unique à Tarapur, au Maharashtra.
200+ produits au catalogue, couvrant les formulations à dose finie et les principes actifs pharmaceutiques, fabriqués sous contrôles de procédé EU-GMP et WHO-GMP.
Installed capacity
Seven production lines, one site
Annual installed capacity at 300 production days a year, company-confirmed in September 2026, with dedicated oncology lines kept separate from the general lines.
-
18.3 M
Flacons liquides d’oncologie / an
-
12 M
Flacons lyophilisés d’oncologie / an
-
240 M
Comprimés et gélules d’oncologie / an
-
21.6 M
Flacons liquides généraux / an
-
67.8 M
Flacons lyophilisés généraux / an
-
60 M
Flacons de Propofol / an
-
360 K
Flacons d’inhalateurs / an
By capability
Four ways into the plant
Manufacturing is the base capability everything else builds on; lyophilization is the specialization behind Naprod's oncology injectables; R&D covers formulation and analytical development. Quality & Regulatory governs what the plant is permitted to ship, and where.
-
Manufacturing
The Tarapur, Maharashtra production floor behind the 200+ product catalog across finished dose forms and APIs, run under EU-GMP and WHO-GMP process controls.
-
Lyophilization
Freeze-drying at commercial scale: 12M dedicated oncology vials and 67.8M general vials a year, the capability most closely tied to Naprod’s oncology franchise.
-
Research & Development
Formulation and analytical development behind the catalog and the 24-product official pipeline, feeding future filings across SRA, ROW, and domestic markets.
-
Quality & Regulatory
15+ international accreditations on the register, including EU-GMP, WHO-GMP, ANVISA, INVIMA, EAEU, UAE MOHAP, and NHRA Bahrain.